191 related articles for article (PubMed ID: 29768183)
1. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
3. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
Shang XB; Yu ZT; Tang P; Zhang XZ
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
[TBL] [Abstract][Full Text] [Related]
4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
7. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
8. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
9. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
Rosell R; Taron M; Barnadas A; Scagliotti G; Sarries C; Roig B
Cancer Control; 2003; 10(4):297-305. PubMed ID: 12915808
[TBL] [Abstract][Full Text] [Related]
11. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R; Liang X; Yu JJ; Reed E
Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
[TBL] [Abstract][Full Text] [Related]
13. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Wu X; Fan W; Xu S; Zhou Y
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5874-9. PubMed ID: 14676109
[TBL] [Abstract][Full Text] [Related]
14. Applications of genomics in NSCLC.
Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B; Davey R
Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair.
Dunkern TR; Fritz G; Kaina B
Mutat Res; 2001 Sep; 486(4):249-58. PubMed ID: 11516928
[TBL] [Abstract][Full Text] [Related]
19. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
[TBL] [Abstract][Full Text] [Related]
20. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
